Risk factors for infection
| . | Rate ratio . | CI (lower) . | CI (upper) . | P . |
|---|---|---|---|---|
| Prior lines of therapy (>3 vs ≤3) | 1.20 | 0.48 | 3.02 | .70 |
| Prior monoclonal antibody therapy (yes or no) | 1.0 | 0.28 | 3.52 | 1.0 |
| Triple class refractory (yes or no) | 1.0 | 0.28 | 3.52 | 1.0 |
| BC (yes or no) | 1.22 | 0.70 | 2.13 | .48 |
| Dose of CAR-T (<300 × 106 cells/kg vs ≥300 × 106 cells/kg) | 0.94 | 0.44 | 1.99 | .87 |
| Infections 30 days before CAR-T (yes or no) | 1.46 | 0.86 | 2.50 | .16 |
| Baseline lymphopenia (ALC <200 cells/mm3 vs ≥200 cells/mm3) | 1.0 | 0.50 | 2.05 | 1.0 |
| Baseline hypogammaglobulinemia (IgG <300 mg/dL vs ≥300 mg/dL) | 0.97 | 0.57 | 1.65 | .91 |
| Post–CAR-T neutropenia (grade ≥3 vs grade <3) | 1.14 | 0.56 | 2.30 | .72 |
| Post–CAR-T lymphopenia (grade ≥3 vs grade <3) | 1.34 | 0.70 | 2.55 | .37 |
| Post–CAR-T hypogammaglobulinemia (IgG <300 mg/dL vs ≥300 mg/dL) | 0.83 | 0.45 | 1.55 | .56 |
| Post–CAR-T best response (≥ partial response (PR) vs < PR) | 0.50 | 0.07 | 3.74 | .50 |
| Tocilizumab (yes or no) | 1.12 | 0.60 | 2.12 | .72 |
| Steroids (yes or no) | 1.12 | 0.66 | 1.89 | .68 |
| Max CRS grade (1-2 vs 0) | 1.06 | 0.42 | 2.64 | .91 |
| . | Rate ratio . | CI (lower) . | CI (upper) . | P . |
|---|---|---|---|---|
| Prior lines of therapy (>3 vs ≤3) | 1.20 | 0.48 | 3.02 | .70 |
| Prior monoclonal antibody therapy (yes or no) | 1.0 | 0.28 | 3.52 | 1.0 |
| Triple class refractory (yes or no) | 1.0 | 0.28 | 3.52 | 1.0 |
| BC (yes or no) | 1.22 | 0.70 | 2.13 | .48 |
| Dose of CAR-T (<300 × 106 cells/kg vs ≥300 × 106 cells/kg) | 0.94 | 0.44 | 1.99 | .87 |
| Infections 30 days before CAR-T (yes or no) | 1.46 | 0.86 | 2.50 | .16 |
| Baseline lymphopenia (ALC <200 cells/mm3 vs ≥200 cells/mm3) | 1.0 | 0.50 | 2.05 | 1.0 |
| Baseline hypogammaglobulinemia (IgG <300 mg/dL vs ≥300 mg/dL) | 0.97 | 0.57 | 1.65 | .91 |
| Post–CAR-T neutropenia (grade ≥3 vs grade <3) | 1.14 | 0.56 | 2.30 | .72 |
| Post–CAR-T lymphopenia (grade ≥3 vs grade <3) | 1.34 | 0.70 | 2.55 | .37 |
| Post–CAR-T hypogammaglobulinemia (IgG <300 mg/dL vs ≥300 mg/dL) | 0.83 | 0.45 | 1.55 | .56 |
| Post–CAR-T best response (≥ partial response (PR) vs < PR) | 0.50 | 0.07 | 3.74 | .50 |
| Tocilizumab (yes or no) | 1.12 | 0.60 | 2.12 | .72 |
| Steroids (yes or no) | 1.12 | 0.66 | 1.89 | .68 |
| Max CRS grade (1-2 vs 0) | 1.06 | 0.42 | 2.64 | .91 |